AbCellera Biologics (ABCL) Non-Current Assets (2020 - 2025)
AbCellera Biologics' Non-Current Assets history spans 6 years, with the latest figure at $660.9 million for Q3 2025.
- For the quarter ending Q3 2025, Non-Current Assets rose 1.68% year-over-year to $660.9 million, compared with a TTM value of $660.9 million through Sep 2025, up 1.68%, and an annual FY2024 reading of $609.2 million, down 1.12% over the prior year.
- Non-Current Assets for Q3 2025 was $660.9 million at AbCellera Biologics, roughly flat from $659.9 million in the prior quarter.
- The five-year high for Non-Current Assets was $660.9 million in Q3 2025, with the low at $220.5 million in Q1 2021.
- Average Non-Current Assets over 5 years is $525.1 million, with a median of $579.2 million recorded in 2025.
- Year-over-year, Non-Current Assets surged 102.26% in 2021 and then fell 10.77% in 2025.
- Tracing ABCL's Non-Current Assets over 5 years: stood at $388.8 million in 2021, then skyrocketed by 32.58% to $515.4 million in 2022, then increased by 19.54% to $616.1 million in 2023, then decreased by 1.12% to $609.2 million in 2024, then rose by 8.48% to $660.9 million in 2025.
- Per Business Quant, the three most recent readings for ABCL's Non-Current Assets are $660.9 million (Q3 2025), $659.9 million (Q2 2025), and $579.2 million (Q1 2025).